Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pruritus (itch) is a frequent, burdensome and difficult-to-treat symptom in patients with cholestasis. Fibrates are currently under investigation for the treatment of primary biliary cholangitis in patients with a suboptimal response to ursodeoxycholic acid. Moreover, there is empirical evidence for a possible antipruritic effect. We aim to prove this in a randomized controlled trial, including patients with cholestatic liver diseases other than primary biliary cholangitis that are accompanied by pruritus. METHODS: A multicenter investigator-initiated, double-blind, randomized placebo-controlled trial to evaluate the effect of bezafibrate on cholestatic pruritus in 84 adult patients with primary biliary cholangitis or primary/secondary sclerosing cholangitis. Primary outcome is the proportion of patients with a reduction of itch intensity of 50% or more (measured on a Visual Analog Scale) after 21 days of treatment with bezafibrate 400 mg qid or placebo. Secondary outcomes include the effect of bezafibrate on a five-dimensional itch score, liver disease-specific quality of life, serum liver tests and autotaxin activity. Safety will be evaluated through serum parameters for kidney function and rhabdomyolysis as well as precise recording of (serious) adverse events. We provide a schematic overview of the study protocol and describe the methods used to recruit and randomize patients, collect and handle data and perform statistical analyses. DISCUSSION: Given its favorable safety profile and anticholestatic properties, bezafibrate may become the new first-line treatment option for treating cholestatic pruritus. TRIAL REGISTRATION: Netherlands Trial Register, ID: NCT02701166 . Registered on 2 March 2016; Netherlands Trial Register, ID: NTR5436 . Registered on 3 August 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729 · cited 5×
“UDCA-responsive patients generally have similar life expectancy as sex- and age-matched controls [4].”
BackgroundInfluentialPeroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473 · cited 1×
“As an agonist of peroxisome proliferator-activated receptors (PPARs), bezafibrate has anti-inflammatory [36–38], anticholestatic [20, 39–42] and antifibrotic [43] properties.”
BackgroundLysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.009 · Cited by 410
Self-citationOral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study
Wolfhagen, F., Sternieri, E., Hop, W., Vitale, G., Bertolotti, M., & Van Buuren, H. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322521 · Cited by 343
Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M. M., Mettang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J., et al. (2012) · Hepatology · doi:10.1002/hep.25748 · Cited by 291
Self-citationTreatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
Effects of long-term rifampicin administration in primary biliary cirrhosis
Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90335-v · Cited by 235
Self-citationCOMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231
Self-citationPruritus in cholestasis: facts and fiction
Beuers, U., Kremer, A. E., Bolier, R., & Elferink, R. P. J. O. (2014) · Hepatology · doi:10.1002/hep.26909 · Cited by 225 · cited 2×
“For example, previous studies described diurnal variation of itch intensity [2, 52] where most patients reported more intense itch in the late evening and early nighttime.”
BackgroundResultSelf-citation
Cited by
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
de Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.001 · Cited by 224
Self-citationYou, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
Gao, L., Wang, L., Woo, E., He, X., Yang, G., Bowlus, C., Leung, P. S. C., & Gershwin, M. E. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08772-7 · Cited by 39
Metadata
- Authors
- the Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group, Bolier, R., de Vries, E. S., Parés, A., Helder, J., Kemper, E. M., Zwinderman, K., Elferink, R. P. O., & Beuers, U.
- Venue
- Trials
- Published
- 2017-05-23
- Volume
- 18
- Issue
- 1
- Pages
- 230-230
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2619280077
- Cited by
- 31
- References
- 19
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s13063-017-1966-8
- The paper
- the Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group, Bolier, R., de Vries, E. S., Parés, A., Helder, J., Kemper, E. M., Zwinderman, K., Elferink, R. P. O., & Beuers, U. (2017). Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/s13063-017-1966-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.